Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
Globe Newswire•06/11/2026•09:00 ET
0
Key Highlights
- ➤C19 Phase 3 trial targets 380 patients across approximately 40 global sites
- ➤Phase A topline efficacy data expected in 2H 2027
- ➤Phase B relapse data expected in 2H 2028
- ➤Q3 GAAP net income $100.7 million, driven by $109.6 million non-cash warrant gain
- ➤Cash, equivalents, securities and restricted cash totaled approximately $77.0 million
Expert Statements
Remy Luthringer, Ph.D., Chief Executive Officer of Minerva Neurosciences
“The recent publication in Schizophrenia Research lays out the approach we are taking at Minerva: developing treatments for negative symptoms beyond dopaminergic mechanisms and testing them in trials designed to separate signal from noise. The psychiatry field has increasingly recognized the importance of finding non-dopaminergic mechanisms in the treatment of schizophrenia, particularly for negative symptoms. Roluperidone is the only late-stage candidate targeting negative symptoms directly. The C19 study, our ongoing Phase 3 trial, is designed to confirm the effect we saw in our prior trials. We remain focused on execution and on track for topline efficacy data in the second half of 2027.”
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027
Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms
Get started
Create a free account to read the full story.